{"id":65185,"date":"2026-05-13T21:58:00","date_gmt":"2026-05-13T13:58:00","guid":{"rendered":"https:\/\/flcube.com\/?p=65185"},"modified":"2026-05-13T21:58:00","modified_gmt":"2026-05-13T13:58:00","slug":"sichuan-biokins-bispecific-adc-iza-bren-receives-nmpa-approval-for-nsclc-clinical-study-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65185","title":{"rendered":"Sichuan Biokin&#8217;s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China"},"content":{"rendered":"\n<p><strong>Sichuan Biokin Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) announced that its <strong>bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren)<\/strong>, co-developed with <strong>Bristol-Myers Squibb<\/strong> (BMS), has received approval from China&#8217;s National Medical Products Administration (NMPA) to proceed with <strong>clinical studies<\/strong> in <strong>locally advanced or metastatic non-small cell lung cancer (NSCLC)<\/strong> with positive driver genes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-regulatory-milestone\">Development &amp; Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506)<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>Bristol-Myers Squibb<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Izalontamab brengitecan (iza-bren)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>First-in-class bispecific antibody-drug conjugate (ADC)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>NSCLC with positive driver genes (combination therapy)<\/td><\/tr><tr><td><strong>Global Clinical Program<\/strong><\/td><td>40+ clinical studies across multiple tumor types<\/td><\/tr><tr><td><strong>Breakthrough Therapy Designations<\/strong><\/td><td>7 (China) + 1 (US)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-clinical-strategy\">Drug Profile &amp; Clinical Strategy<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-novel-bispecific-adc-platform\">Novel Bispecific ADC Platform<\/h3>\n\n\n\n<p>Iza-bren represents a <strong>first-in-class, new-concept therapeutic<\/strong> leveraging bispecific antibody technology combined with cytotoxic payload delivery, designed to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Target <strong>multiple tumor-associated antigens simultaneously<\/strong><\/li>\n\n\n\n<li>Enhance <strong>tumor specificity and payload delivery<\/strong><\/li>\n\n\n\n<li>Overcome resistance mechanisms seen with single-target agents<\/li>\n\n\n\n<li>Provide <strong>synergistic anti-tumor activity<\/strong> in combination regimens<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-expanded-clinical-development\">Expanded Clinical Development<\/h3>\n\n\n\n<p>The newly approved study will evaluate iza-bren <strong>in combination with other drugs<\/strong> specifically in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Locally advanced or metastatic NSCLC<\/strong><\/li>\n\n\n\n<li>Patients with <strong>positive driver gene mutations<\/strong><\/li>\n\n\n\n<li>Setting builds on established safety profile from ongoing global trials<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-priority-review-pipeline\">Priority Review Pipeline<\/h2>\n\n\n\n<p>Beyond the newly approved NSCLC indication, iza-bren is currently under <strong>priority review<\/strong> in China for two additional indications:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Status<\/th><th>Market Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Locally advanced or metastatic nasopharyngeal carcinoma<\/strong><\/td><td>Priority review<\/td><td>High prevalence in Asia-Pacific region<\/td><\/tr><tr><td><strong>Recurrent or metastatic esophageal squamous cell carcinoma<\/strong><\/td><td>Priority review<\/td><td>Significant unmet need in gastrointestinal oncology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-impact\">Strategic Partnership Impact<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-sichuan-biokin\">For Sichuan Biokin<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global validation<\/strong>: BMS partnership provides international credibility and development resources<\/li>\n\n\n\n<li><strong>Platform expansion<\/strong>: Success in multiple tumor types validates bispecific ADC platform<\/li>\n\n\n\n<li><strong>Commercial potential<\/strong>: Multiple priority reviews position for rapid market entry across indications<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-bristol-myers-squibb\">For Bristol-Myers Squibb<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation pipeline<\/strong>: Access to novel bispecific ADC technology from Chinese biotech leader<\/li>\n\n\n\n<li><strong>Asia-Pacific strategy<\/strong>: Strengthened position in high-growth Chinese oncology market<\/li>\n\n\n\n<li><strong>Combination opportunities<\/strong>: Potential to pair with BMS&#8217;s existing immuno-oncology portfolio<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Market Growth<\/strong>: Global ADC market projected to reach <strong>$16.4 billion by 2028<\/strong>, with China representing fastest-growing segment<\/li>\n\n\n\n<li><strong>NSCLC Treatment Gap<\/strong>: Despite advances in targeted therapy, significant unmet need remains for patients with driver-positive disease progressing on current regimens<\/li>\n\n\n\n<li><strong>Chinese Innovation Leadership<\/strong>: Sichuan Biokin exemplifies China&#8217;s evolution from generic manufacturer to innovative biologics developer<\/li>\n\n\n\n<li><strong>Regulatory Acceleration<\/strong>: Breakthrough Therapy Designations and priority reviews reflect NMPA&#8217;s commitment to expediting innovative cancer therapies<\/li>\n<\/ul>\n\n\n\n<p>The expanded clinical program positions iza-bren as a <strong>multi-indication oncology asset<\/strong> with potential to address significant unmet needs across multiple solid tumor types.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial potential for iza-bren. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688506_20260513_5MNC.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20260513_5MNC.\"><\/object><a id=\"wp-block-file--media-18eaaf49-3dc0-4b49-95c2-db695111959d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688506_20260513_5MNC.pdf\">688506_20260513_5MNC<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688506_20260513_5MNC.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-18eaaf49-3dc0-4b49-95c2-db695111959d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC) izalontamab&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,151,428,16,62,857],"class_list":["post-65185","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-bristol-myers-squibb","tag-cancer","tag-clinical-trial-approval-initiation","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sichuan Biokin&#039;s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), co-developed with Bristol-Myers Squibb (BMS), has received approval from China&#039;s National Medical Products Administration (NMPA) to proceed with clinical studies in locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive driver genes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65185\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin&#039;s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China\" \/>\n<meta property=\"og:description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), co-developed with Bristol-Myers Squibb (BMS), has received approval from China&#039;s National Medical Products Administration (NMPA) to proceed with clinical studies in locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive driver genes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65185\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T13:58:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65185#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65185\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin&#8217;s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China\",\"datePublished\":\"2026-05-13T13:58:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65185\"},\"wordCount\":469,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Bristol-Myers Squibb\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65185#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65185\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65185\",\"name\":\"Sichuan Biokin's Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-13T13:58:00+00:00\",\"description\":\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), co-developed with Bristol-Myers Squibb (BMS), has received approval from China's National Medical Products Administration (NMPA) to proceed with clinical studies in locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive driver genes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65185#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65185\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65185#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin&#8217;s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin's Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), co-developed with Bristol-Myers Squibb (BMS), has received approval from China's National Medical Products Administration (NMPA) to proceed with clinical studies in locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive driver genes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65185","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin's Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China","og_description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), co-developed with Bristol-Myers Squibb (BMS), has received approval from China's National Medical Products Administration (NMPA) to proceed with clinical studies in locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive driver genes.","og_url":"https:\/\/flcube.com\/?p=65185","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-13T13:58:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65185#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65185"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin&#8217;s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China","datePublished":"2026-05-13T13:58:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65185"},"wordCount":469,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Biokin Pharmaceutical","Bristol-Myers Squibb","Cancer","Clinical trial approval \/ initiation","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65185#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65185","url":"https:\/\/flcube.com\/?p=65185","name":"Sichuan Biokin's Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-13T13:58:00+00:00","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), co-developed with Bristol-Myers Squibb (BMS), has received approval from China's National Medical Products Administration (NMPA) to proceed with clinical studies in locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive driver genes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65185#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65185"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65185#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin&#8217;s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65185"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65185\/revisions"}],"predecessor-version":[{"id":65188,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65185\/revisions\/65188"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}